Viatris Inc. Stock Falls Wednesday, Underperforms Market
MarketWatch Automated·
Viatris Inc. stock falls Thursday, underperforms market
MSN·- Viatris Inc. shares slipped 7.71% to $16.29 on Thursday, marking the stock's second consecutive day of losses. - The decline occurred during an overall poor trading session for the broader stock market. - The S&P 500 Index fell 0.18% to 7,709.96 and the Dow Jones Industrial Average dropped 0.85% to 53,885.10.Viatris Inc. Stock Falls Friday, Underperforms Market
MarketWatch Automated·Weekly Buzz:CIPLA, VTRS Win FDA Nod; BSX Cuts Jobs; ARGX Snaps Up FBRX; JNJ, GSK Strike Deals
rttnews·- The healthcare sector experienced an active week driven by key regulatory approvals, restructuring programs, multi-billion dollar corporate acquisitions, and clinical trial outcomes across various therapeutic areas. - Major regulatory updates included FDA and European Commission approvals for vaccines, therapies, and generic treatments from companies such as Pfizer-BioNTech, Cipla, Viatris, and AbbVie. - Industry players engaged in significant strategic transactions, such as Boston Scientific launching an $800 million restructuring plan and Johnson & Johnson agreeing to a $5.5 billion talc settlement.Viatris Inc. Stock Rises Tuesday, Outperforms Market
MarketWatch Automated·Viatris Inc. Stock Rises Monday, Outperforms Market
MarketWatch Automated·